Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07806175
PHASE1/PHASE2

A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors

Sponsor: Rongchang Pharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.

Official title: A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 Tablets in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

486

Start Date

2026-09-15

Completion Date

2029-08-15

Last Updated

2026-09-08

Healthy Volunteers

No

Interventions

DRUG

RCZY690 Tablets

Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.

DRUG

RCZY690 tables

Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.

Locations (8)

Cancer Hospital, CAMS

Beijing, Beijing Municipality, China

Hunan Provincial Cancer Hospital

Hunan, Changsha, China

Zhejiang Cancer Hospital

Zhejiang, Hangzhou, China

Shandong Cancer Hospital

Shandong, Jinan, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Shanxi Provincial Cancer Hospital

Shanxi, Taiyuan, China

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China